- Introduction
- Materials and Methods
- Results
- Detection of infectious DENV–Ab immune complex using FcγR-expressing cells in marmosets passively transferred with mAbs.
- Detection of mouse IgG Ab in plasma samples from marmosets after administration of mAbs.
- Absence of marmoset anti-DENV IgM and IgG on days 0, 2, and 4 after DENV inoculation.
- Neutralizing Ab in marmosets after Ab administration and DENV inoculation.
- Limited effect of administration of a DENV infection-enhancing mAb in marmosets.
- Discussion
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI, 2013. The global distribution and burden of dengue. Nature 496: 504–507.
-
2.
WHO, 2009. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. Geneva: World Health Organization.
-
3.
Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB, 1984. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653–669.
-
4.
Guzman MG, Kouri GP, Bravo J, Calunga M, Soler M, Vazquez S, Venereo C, 1984. Dengue haemorrhagic fever in Cuba. I. Serological confirmation of clinical diagnosis. Trans R Soc Trop Med Hyg 78: 235–238.
-
5.
Guzman MG, Alvarez M, Halstead SB, 2013. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 158: 1445–1459.
-
6.
Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS, 1989. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40: 444–451.
-
7.
Halstead SB, O'Rourke EJ, 1977. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146: 201–217.
-
8.
Kontny U, Kurane I, Ennis FA, 1988. Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells. J Virol 62: 3928–3933.
-
9.
Ruangjirachuporn W, Boonpucknavig S, Nimmanitya S, 1979. Circulating immune complexes in serum from patients with dengue haemorrhagic fever. Clin Exp Immunol 36: 46–53.
-
10.
Wang WK, Chen HL, Yang CF, Hsieh SC, Juan CC, Chang SM, Yu CC, Lin LH, Huang JH, King CC, 2006. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis 43: 1023–1030.
-
11.
Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I, 2011. Detection of higher levels of dengue viremia using FcγR-expressing BHK-21 cells than FcγR-negative cells in secondary infection but not in primary infection. J Infect Dis 203: 1405–1414.
-
12.
Kliks SC, Nimmanitya S, Nisalak A, Burke DS, 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38: 411–419.
-
13.
Ito M, Mukai RZ, Takasaki T, Kotaki A, Kurane I, 2010. Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus. Arch Virol 155: 1617–1624.
-
14.
Moi ML, Takasaki T, Saijo M, Kurane I, 2013. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection. Trans R Soc Trop Med Hyg 107: 51–58.
-
15.
Ng JK, Zhang SL, Tan HC, Yan B, Maria Martinez Gomez J, Tan WY, Lam JH, Tan GK, Ooi EE, Alonso S, 2014. First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. PLoS Pathog 10: e1004031.
-
16.
Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ, 2007. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA 104: 9422–9427.
-
17.
Halstead SB, Shotwell H, Casals J, 1973. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis 128: 15–22.
-
18.
Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E, 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790.
-
19.
Omatsu T, Moi ML, Hirayama T, Takasaki T, Nakamura S, Tajima S, Ito M, Yoshida T, Saito A, Katakai Y, Akari H, Kurane I, 2011. Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity. J Gen Virol 92: 2272–2280.
-
20.
Moi ML, Takasaki T, Omatsu T, Nakamura S, Katakai Y, Ami Y, Suzaki Y, Saijo M, Akari H, Kurane I, 2014. Demonstration of marmosets (Callithrix jacchus) as a non-human primate model for secondary dengue virus infection: high levels of viraemia and serotype cross-reactive antibody responses consistent with secondary infection of humans. J Gen Virol 95: 591–600.
-
21.
Henchal EA, Gentry MK, McCown JM, Brandt WE, 1982. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 31: 830–836.
-
22.
Moi ML, Takasaki T, Saijo M, Kurane I, 2014. Determination of antibody concentration as the main parameter in a dengue virus antibody-dependent enhancement assay using FcγR-expressing BHK cells. Arch Virol 159: 103–116.
-
23.
Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I, 2010. Development of an antibody-dependent enhancement assay for dengue virus using stable BHK-21 cell lines expressing Fc gammaRIIA. J Virol Methods 163: 205–209.
-
24.
Ito M, Takasaki T, Yamada K, Nerome R, Tajima S, Kurane I, 2004. Development and evaluation of fluorogenic TaqMan reverse transcriptase PCR assays for detection of dengue virus types 1 to 4. J Clin Microbiol 42: 5935–5937.
-
25.
Moi ML, Lim CK, Chua KB, Takasaki T, Kurane I, 2012. Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells. PLoS Negl Trop Dis 6: e1536.
-
26.
Ito M, Katakai Y, Ono F, Akari H, Mukai RZ, Takasaki T, Kotaki A, Kurane I, 2011. Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes. Arch Virol 156: 1073–1077.
-
27.
Boonnak K, Slike BM, Donofrio GC, Marovich MA, 2013. Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J Immunol 190: 5659–5665.
-
28.
Chan KR, Ong EZ, Tan HC, Zhang SL, Zhang Q, Tang KF, Kaliaperumal N, Lim AP, Hibberd ML, Chan SH, Connolly JE, Krishnan MN, Lok SM, Hanson BJ, Lin CN, Ooi EE, 2014. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc Natl Acad Sci USA 111: 2722–2727.
-
29.
Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM, 2010. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 10: 712–722.
-
30.
Ubol S, Halstead SB, 2010. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol 17: 1829–1835.
-
31.
Ubol S, Phuklia W, Kalayanarooj S, Modhiran N, 2010. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis 201: 923–935.
-
32.
Halstead SB, 2009. Pathogenesis: Risk factors prior to infection. Halstead SB, Pasvol G, Hoffman SL, ed. Dengue (Tropical Medicine: Science and Practice). London, United Kingdom: Imperial College Press, 219–256.
-
33.
Halstead SB, 1979. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140: 527–533.
-
34.
The Marmoset Genome Sequencing and Analysis Consortium, 2014. The common marmoset genome provides insight into primate biology and evolution. Nat Genet 46: 850–857.
-
35.
Chan KR, Ong EZ, Tan HC, Zhang SL, Zhang Q, Tang KF, Kaliaperumal N, Lim AP, Hibberd ML, Chan SH, Connolly JE, Krishnan MN, Lok SM, Hanson BJ, Lin CN, Ooi EE, 2014. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc Natl Acad Sci USA 111: 2722–2777.
-
36.
Nimmerjahn F, Lux A, 2014. LILR-B1 blocks activating FcγR signaling to allow antibody dependent enhancement of dengue virus infection. Proc Natl Acad Sci USA 111: 2404–2405.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 499 | 427 | 9 |
| Full Text Views | 329 | 7 | 0 |
| PDF Downloads | 114 | 8 | 0 |
Formation of Infectious Dengue Virus–Antibody Immune Complex In Vivo in Marmosets (Callithrix jacchus) After Passive Transfer of Anti-Dengue Virus Monoclonal Antibodies and Infection with Dengue Virus
Meng Ling Moi
Meng Ling Moi
Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; Division of Experimental Animal Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan; Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan; College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan; National Institute of Infectious Diseases, Tokyo, Japan
Search for other papers by Meng Ling Moi in
Current site
Google Scholar
PubMed
Search for other papers by Meng Ling Moi in
Current site
Google Scholar
PubMed
Yasushi Ami
Yasushi Ami
Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; Division of Experimental Animal Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan; Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan; College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan; National Institute of Infectious Diseases, Tokyo, Japan
Search for other papers by Yasushi Ami in
Current site
Google Scholar
PubMed
Search for other papers by Yasushi Ami in
Current site
Google Scholar
PubMed
Kenji Shirai
Kenji Shirai
Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; Division of Experimental Animal Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan; Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan; College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan; National Institute of Infectious Diseases, Tokyo, Japan
Search for other papers by Kenji Shirai in
Current site
Google Scholar
PubMed
Search for other papers by Kenji Shirai in
Current site
Google Scholar
PubMed
Chang-Kweng Lim
Chang-Kweng Lim
Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; Division of Experimental Animal Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan; Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan; College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan; National Institute of Infectious Diseases, Tokyo, Japan
Search for other papers by Chang-Kweng Lim in
Current site
Google Scholar
PubMed
Search for other papers by Chang-Kweng Lim in
Current site
Google Scholar
PubMed
Yuriko Suzaki
Yuriko Suzaki
Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; Division of Experimental Animal Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan; Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan; College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan; National Institute of Infectious Diseases, Tokyo, Japan
Search for other papers by Yuriko Suzaki in
Current site
Google Scholar
PubMed
Search for other papers by Yuriko Suzaki in
Current site
Google Scholar
PubMed
Yuka Saito
Yuka Saito
Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; Division of Experimental Animal Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan; Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan; College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan; National Institute of Infectious Diseases, Tokyo, Japan
Search for other papers by Yuka Saito in
Current site
Google Scholar
PubMed
Search for other papers by Yuka Saito in
Current site
Google Scholar
PubMed
Kazutaka Kitaura
Kazutaka Kitaura
Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; Division of Experimental Animal Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan; Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan; College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan; National Institute of Infectious Diseases, Tokyo, Japan
Search for other papers by Kazutaka Kitaura in
Current site
Google Scholar
PubMed
Search for other papers by Kazutaka Kitaura in
Current site
Google Scholar
PubMed
Masayuki Saijo
Masayuki Saijo
Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; Division of Experimental Animal Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan; Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan; College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan; National Institute of Infectious Diseases, Tokyo, Japan
Search for other papers by Masayuki Saijo in
Current site
Google Scholar
PubMed
Search for other papers by Masayuki Saijo in
Current site
Google Scholar
PubMed
Ryuji Suzuki
Ryuji Suzuki
Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; Division of Experimental Animal Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan; Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan; College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan; National Institute of Infectious Diseases, Tokyo, Japan
Search for other papers by Ryuji Suzuki in
Current site
Google Scholar
PubMed
Search for other papers by Ryuji Suzuki in
Current site
Google Scholar
PubMed
Ichiro Kurane
Ichiro Kurane
Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; Division of Experimental Animal Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan; Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan; College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan; National Institute of Infectious Diseases, Tokyo, Japan
Search for other papers by Ichiro Kurane in
Current site
Google Scholar
PubMed
Search for other papers by Ichiro Kurane in
Current site
Google Scholar
PubMed
Tomohiko Takasaki
Tomohiko Takasaki
Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan; Division of Experimental Animal Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan; Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan; College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan; National Institute of Infectious Diseases, Tokyo, Japan
Search for other papers by Tomohiko Takasaki in
Current site
Google Scholar
PubMed
Search for other papers by Tomohiko Takasaki in
Current site
Google Scholar
PubMed
Infection with a dengue virus (DENV) serotype induces cross-reactive, weakly neutralizing antibodies to different dengue serotypes. It has been postulated that cross-reactive antibodies form a virus–antibody immune complex and enhance DENV infection of Fc gamma receptor (FcγR)-bearing cells. We determined whether infectious DENV–antibody immune complex is formed in vivo in marmosets after passive transfer of DENV-specific monoclonal antibody (mAb) and DENV inoculation and whether infectious DENV–antibody immune complex is detectable using FcγR-expressing cells. Marmosets showed that DENV–antibody immune complex was exclusively infectious to FcγR-expressing cells on days 2, 4, and 7 after passive transfer of each of the mAbs (mAb 4G2 and mAb 6B6C) and DENV inoculation. Although DENV–antibody immune complex was detected, contribution of the passively transferred antibody to overall viremia levels was limited in this study. The results indicate that DENV cross-reactive antibodies form DENV–antibody immune complex in vivo, which is infectious to FcγR-bearing cells but not FcγR-negative cells.
Author Notes
Financial support: This work was supported by Research on Emerging and Re-Emerging Infectious Diseases Grants H23-shinkou-ippan-010 and H26-shinkou-jitsuyouka-007 from the Ministry of Health, Labour and Welfare, Japan and Kiban B Grant-in-Aid for Scientific Research 25293112 and Young Scientists B Grant-in-Aid for Scientific Research 26870872 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Authors' addresses: Meng Ling Moi, Chang-Kweng Lim, Masayuki Saijo, and Tomohiko Takasaki, Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan, E-mails: sherry@nih.go.jp, ck@nih.go.jp, msaijo@nih.go.jp, and takasaki@nih.go.jp. Yasushi Ami and Yuriko Suzaki, Division of Experimental Animal Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan, E-mails: yami@nih.go.jp and ysuzaki@nih.go.jp. Kenji Shirai, Kazutaka Kitaura, and Ryuji Suzuki, Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan, E-mails: k.shirai0727@gmail.com, kitaura@nih.go.jp, and r-suzuki@sagamihara-hosp.gr.jp. Yuka Saito, Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan, and College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan, E-mail: saito-y@nih.go.jp. Ichiro Kurane, National Institute of Infectious Diseases, Tokyo, Japan, E-mail: kurane@nih.go.jp.
- Introduction
- Materials and Methods
- Results
- Detection of infectious DENV–Ab immune complex using FcγR-expressing cells in marmosets passively transferred with mAbs.
- Detection of mouse IgG Ab in plasma samples from marmosets after administration of mAbs.
- Absence of marmoset anti-DENV IgM and IgG on days 0, 2, and 4 after DENV inoculation.
- Neutralizing Ab in marmosets after Ab administration and DENV inoculation.
- Limited effect of administration of a DENV infection-enhancing mAb in marmosets.
- Discussion
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI, 2013. The global distribution and burden of dengue. Nature 496: 504–507.
-
2.
WHO, 2009. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. Geneva: World Health Organization.
-
3.
Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB, 1984. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653–669.
-
4.
Guzman MG, Kouri GP, Bravo J, Calunga M, Soler M, Vazquez S, Venereo C, 1984. Dengue haemorrhagic fever in Cuba. I. Serological confirmation of clinical diagnosis. Trans R Soc Trop Med Hyg 78: 235–238.
-
5.
Guzman MG, Alvarez M, Halstead SB, 2013. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 158: 1445–1459.
-
6.
Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS, 1989. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40: 444–451.
-
7.
Halstead SB, O'Rourke EJ, 1977. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146: 201–217.
-
8.
Kontny U, Kurane I, Ennis FA, 1988. Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells. J Virol 62: 3928–3933.
-
9.
Ruangjirachuporn W, Boonpucknavig S, Nimmanitya S, 1979. Circulating immune complexes in serum from patients with dengue haemorrhagic fever. Clin Exp Immunol 36: 46–53.
-
10.
Wang WK, Chen HL, Yang CF, Hsieh SC, Juan CC, Chang SM, Yu CC, Lin LH, Huang JH, King CC, 2006. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis 43: 1023–1030.
-
11.
Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I, 2011. Detection of higher levels of dengue viremia using FcγR-expressing BHK-21 cells than FcγR-negative cells in secondary infection but not in primary infection. J Infect Dis 203: 1405–1414.
-
12.
Kliks SC, Nimmanitya S, Nisalak A, Burke DS, 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38: 411–419.
-
13.
Ito M, Mukai RZ, Takasaki T, Kotaki A, Kurane I, 2010. Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus. Arch Virol 155: 1617–1624.
-
14.
Moi ML, Takasaki T, Saijo M, Kurane I, 2013. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection. Trans R Soc Trop Med Hyg 107: 51–58.
-
15.
Ng JK, Zhang SL, Tan HC, Yan B, Maria Martinez Gomez J, Tan WY, Lam JH, Tan GK, Ooi EE, Alonso S, 2014. First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. PLoS Pathog 10: e1004031.
-
16.
Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ, 2007. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA 104: 9422–9427.
-
17.
Halstead SB, Shotwell H, Casals J, 1973. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis 128: 15–22.
-
18.
Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E, 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790.
-
19.
Omatsu T, Moi ML, Hirayama T, Takasaki T, Nakamura S, Tajima S, Ito M, Yoshida T, Saito A, Katakai Y, Akari H, Kurane I, 2011. Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity. J Gen Virol 92: 2272–2280.
-
20.
Moi ML, Takasaki T, Omatsu T, Nakamura S, Katakai Y, Ami Y, Suzaki Y, Saijo M, Akari H, Kurane I, 2014. Demonstration of marmosets (Callithrix jacchus) as a non-human primate model for secondary dengue virus infection: high levels of viraemia and serotype cross-reactive antibody responses consistent with secondary infection of humans. J Gen Virol 95: 591–600.
-
21.
Henchal EA, Gentry MK, McCown JM, Brandt WE, 1982. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 31: 830–836.
-
22.
Moi ML, Takasaki T, Saijo M, Kurane I, 2014. Determination of antibody concentration as the main parameter in a dengue virus antibody-dependent enhancement assay using FcγR-expressing BHK cells. Arch Virol 159: 103–116.
-
23.
Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I, 2010. Development of an antibody-dependent enhancement assay for dengue virus using stable BHK-21 cell lines expressing Fc gammaRIIA. J Virol Methods 163: 205–209.
-
24.
Ito M, Takasaki T, Yamada K, Nerome R, Tajima S, Kurane I, 2004. Development and evaluation of fluorogenic TaqMan reverse transcriptase PCR assays for detection of dengue virus types 1 to 4. J Clin Microbiol 42: 5935–5937.
-
25.
Moi ML, Lim CK, Chua KB, Takasaki T, Kurane I, 2012. Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells. PLoS Negl Trop Dis 6: e1536.
-
26.
Ito M, Katakai Y, Ono F, Akari H, Mukai RZ, Takasaki T, Kotaki A, Kurane I, 2011. Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes. Arch Virol 156: 1073–1077.
-
27.
Boonnak K, Slike BM, Donofrio GC, Marovich MA, 2013. Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J Immunol 190: 5659–5665.
-
28.
Chan KR, Ong EZ, Tan HC, Zhang SL, Zhang Q, Tang KF, Kaliaperumal N, Lim AP, Hibberd ML, Chan SH, Connolly JE, Krishnan MN, Lok SM, Hanson BJ, Lin CN, Ooi EE, 2014. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc Natl Acad Sci USA 111: 2722–2727.
-
29.
Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM, 2010. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 10: 712–722.
-
30.
Ubol S, Halstead SB, 2010. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol 17: 1829–1835.
-
31.
Ubol S, Phuklia W, Kalayanarooj S, Modhiran N, 2010. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis 201: 923–935.
-
32.
Halstead SB, 2009. Pathogenesis: Risk factors prior to infection. Halstead SB, Pasvol G, Hoffman SL, ed. Dengue (Tropical Medicine: Science and Practice). London, United Kingdom: Imperial College Press, 219–256.
-
33.
Halstead SB, 1979. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140: 527–533.
-
34.
The Marmoset Genome Sequencing and Analysis Consortium, 2014. The common marmoset genome provides insight into primate biology and evolution. Nat Genet 46: 850–857.
-
35.
Chan KR, Ong EZ, Tan HC, Zhang SL, Zhang Q, Tang KF, Kaliaperumal N, Lim AP, Hibberd ML, Chan SH, Connolly JE, Krishnan MN, Lok SM, Hanson BJ, Lin CN, Ooi EE, 2014. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc Natl Acad Sci USA 111: 2722–2777.
-
36.
Nimmerjahn F, Lux A, 2014. LILR-B1 blocks activating FcγR signaling to allow antibody dependent enhancement of dengue virus infection. Proc Natl Acad Sci USA 111: 2404–2405.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 499 | 427 | 9 |
| Full Text Views | 329 | 7 | 0 |
| PDF Downloads | 114 | 8 | 0 |